Prognostic value of the Glasgow prognostic score in lung cancer: evidence from 10 studies
Authors:
- 24 October 2017
- journal article
- research article
- Published by SAGE Publications in The International Journal of Biological Markers
- Vol. 33 (2) , 201-207
Abstract
Objective: To conduct a meta-analysis of prospective and retrospective studies to reveal the relationship between the Glasgow prognostic score (GPS) and overall survival (OS) or progression-free survival (PFS) in patients with lung cancer. Methods: Correlative studies were included by searching the databases of PubMed, Web of Science, Embase, and PubMed Cochrane Library until April 16, 2017. We combined the hazard ratios (HRs) and 95% confidence intervals (CIs) to assess the correlation between GPS and OS or PFS in patients with lung cancer. Results: Ten studies involving 5,369 participants from several regions were identified through searching databases. In a pooled analysis of all studies, elevated GPS was associated with poorer OS (HR = 2.058; 95% CI, 1.51-2.80; p<0.05). However, the combined data showed no significant relationship between the GPS of 1 or 2, and PFS, respectively. Subgroup analysis showed that the patients with GPS ≥1 had poorer OS compared with those with GPS = 0 (HR = 2.01; 95% CI, 1.75-2.32; p<0.001). A similar trend was observed in patients receiving chemotherapy (HR = 1.66; 95% CI, 1.17-2.36; p<0.05) and surgery (HR = 2.88; 95% CI, 1.59-5.22; p<0.001) when stratified by treatment. Conclusions: Increased level of GPS may have a prognostic value in lung cancer. We detected a statistical difference in the association of elevated GPS and poorer OS, though the association was not significant in PFS settings. However, further studies are warranted to draw firm conclusions.Keywords
This publication has 38 references indexed in Scilit:
- Prognostic value of C-reactive protein and neutrophil-to-lymphocyte ratio in patients with hepatocellular carcinomaBMC Cancer, 2013
- Cancer treatment and survivorship statistics, 2012CA: A Cancer Journal for Clinicians, 2012
- Clinical Utility of the Pretreatment Glasgow Prognostic Score in Patients with Advanced Inoperable Non-small Cell Lung CancerJournal of Thoracic Oncology, 2012
- A comparison of inflammation-based prognostic scores in patients with cancer. A Glasgow Inflammation Outcome StudyEuropean Journal of Cancer, 2011
- Reduced Lung-Cancer Mortality with Low-Dose Computed Tomographic ScreeningNew England Journal of Medicine, 2011
- The relationship between the insulin-like growth factor-1 axis, weight loss, an inflammation-based score and survival in patients with inoperable non-small cell lung cancerClinical Nutrition, 2010
- Role of Systemic Inflammatory Response in Predicting Survival in Patients with Primary Operable CancerFuture Oncology, 2009
- C-reactive protein in liver cancer surgeryEuropean Journal of Surgical Oncology, 2008
- Practical methods for incorporating summary time-to-event data into meta-analysisTrials, 2007
- Measuring inconsistency in meta-analysesBMJ, 2003